Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a blood filter save stroke patients?

NCT ID NCT07127484

Disease control Sponsor: First Affiliated Hospital of Wannan Medical College Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 04, 2026 · Updated 2 times

Summary

This study tests whether a procedure called hemoadsorption, which filters the blood, can help people with severe ischemic stroke. Researchers will compare standard care plus hemoadsorption to standard care alone in 116 adults. The goal is to see if the procedure reduces the chance of severe disability or death.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
hemoadsorption (a blood-filtering procedure)
What this could lead to
If it works, this could offer a new way to reduce disability after severe stroke by filtering harmful substances from the blood.
What could go wrong
This is an early-stage trial with only 116 participants, so results may not apply to all stroke patients. The procedure also carries risks like bleeding or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 116 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1.18 years ≤ age \< 80 years; 2.Pre-stroke mRS score ≤ 1; 3.Anterior circulation cerebral infarction within 48 hours of onset, meeting at least one of the following: 1. 15≤ NIHSS score ≤32; 2. 3\<GCS score ≤12; 3. CT hypodensity area \>1/2 of the MCA territory; 4.hs-CRP ≥2 mg/L at randomization; 5.If reperfusion therapy is performed, no improvement in NIHSS score (still ≤32) post-treatment; 6.Signed informed consent obtained. Exclusion Criteria: 1. Hemorrhagic transformation of PH2 type prior to randomization; 2. Brain herniation or decompressive craniectomy performed before randomization; 3. Hemodynamic instability refractory to medical correction (systolic blood pressure \<70 mmHg or diastolic blood pressure \<50 mmHg) or decompensated heart failure (NYHA Class III or IV); 4. Severe hepatic impairment (defined as ALT \>2 times the upper limit of normal or AST \>2 times the upper limit of normal) and renal impairment (defined as serum creatinine \>1.5 times the upper limit of normal or estimated glomerular filtration rate \[eGFR\] \<50 mL/min); 5. Coagulopathy or thrombocytopenia (platelet count \<100×10⁹/L); 6. Deep vein thrombosis (DVT) of the lower extremities before randomization; 7. Life expectancy \<90 days due to malignancy; 8. Participation in another drug or device clinical trial within the past 30 days or ongoing enrollment in such trials; 9. Women of childbearing potential with a negative pregnancy test who refuse to use effective contraception, or pregnant/lactating women; 10. Absolute contraindications to hemoadsorption therapy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hemoadsorption are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hemoadsorption Ischemic stroke

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The First Affiliated Hospital of Wannan Medical University (Yijishan Hospital)

    RECRUITING

    Wuhu, Anhui, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.